Two new US Patents for the Australian Life Science sector

A massive 333 Life Science patents (classification A61K) were issued by the US Patent and Trademark Office on Tuesday 20 September 2016 (click here). Two went to Australian assignees.

US Patent 9,446,057 was granted to Mayne Pharma (ASX: MYX) for Controlled release doxycycline. This patent covers Mayne's formulation of that antibiotic, where the moist granulated mass of drug is extruded, cut, spheronized and dried to form pellets with a better release profile than other formulations.

US Patent 9,447,080 was granted to Biota for Viral polymerase inhibitors. This patent covers small molecule inhibitors to the polymerase enzyme of Hepatitis C Virus​. Biota, which hailed from Melbourne and was for many years a leader in the Australian Life Sciences sector, is now Aviragen Therapeutics (Nasdaq: AVIR) of Alpharetta, Ga.  

​Over the last twelve months the Australian Life Science sector has been granted 122 US patents, versus 127 in the previous corresponding period. ​

To look at US Life Science patent issuance since the beginning of 2014 to Australian assignees, click here. For  US Life Science patent issuance to New Zealand assignees click here.